13F Holdings
中文EN

VIR Vir Biotechnology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1706431 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,696.0%
TTM net income YoY63.0%
TTM EPS YoY67.4%
Revenue 3-yr CAGR36.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-69.8%
Net margin-61.0%
FCF margin-46.8%
EBITDA margin-66.1%

Returns

ROE-21.8%
ROA-17.3%
ROIC (approx.)-25.6%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$68.56M$74.20M$86.18M$1.62B$1.10B
Cost of revenue$26,000$845,000$2.77M$146.32M$65.86M
Gross profit$68.53M$73.36M$83.42M$1.47B$1.03B
R&D expense$455.97M$506.50M$579.72M$474.65M$448.01M
SG&A expense$92.07M$119.03M$174.44M$161.76M$160.79M
Operating income-$479.33M-$587.16M-$684.30M$833.07M$420.75M
Pretax income-$437.77M-$523.11M-$628.19M$754.28M$549.80M
Income tax$217,000-$1.15M-$13.08M$238.44M$21.22M
Net income-$437.99M-$521.96M-$615.06M$515.84M$528.58M
EBITDA-$467.65M-$572.61M-$664.85M$839.85M$426.03M
EPS (basic)-3.16-3.83-4.593.894.07
EPS (diluted)-3.16-3.83-4.593.833.96
Weighted avg. shares (diluted)138.52M136.25M134.13M134.81M133.44M
Balance sheet
Cash & equivalents$232.19M$318.69M$241.58M$867.97M$363.42M
Short-term investments$228.75M$678.05M$1.27B$1.52B$217.18M
Receivables———$0$773.08M
Current assets$514.08M$1.04B$1.59B$2.52B$1.56B
PP&E, net$55.62M$63.18M$96.02M$105.61M$42.83M
Goodwill$16.94M$16.94M$16.94M$16.94M$16.94M
Intangibles$7.85M$8.12M$22.57M$32.76M$33.29M
Total assets$1.00B$1.40B$1.92B$2.80B$1.95B
Current liabilities$92.81M$119.66M$175.41M$511.03M$341.24M
Total liabilities$237.55M$248.43M$328.82M$724.12M$522.42M
Shareholders' equity$765.28M$1.15B$1.59B$2.08B$1.43B
Shares outstanding139.47M136.96M134.78M133.24M131.16M
Cash flow statement
Operating cash flow-$391.78M-$446.35M-$778.78M$1.66B-$47.59M
Capital expenditure$4.83M$7.30M$21.57M$68.01M$21.82M
Free cash flow-$396.61M-$453.65M-$800.36M$1.60B-$69.41M
Investing cash flow$310.37M$499.37M$164.63M-$1.19B-$140.81M
Financing cash flow$3.79M$4.39M$7.48M$34.76M$100.33M
Depreciation & amortization$11.68M$14.56M$19.45M$6.78M$5.28M
Stock-based compensation$49.07M$78.46M$111.32M$102.08M$83.78M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.